Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor

Science

Volumn 280, Issue 5364, 1998, Pages 734-737

  Duesbery, Nicholas S ^a   Webb, Craig P ^a   Leppla, Stephen H ^b   Gordon, Valery M ^b   Klimpel, Kurt R ^b,f   Copeland, Terry D ^a   Ahn, Natalie G ^c   Oskarsson, Marianne K ^a   Fukasawa, Kenji ^d   Paull, Ken D ^e   Vande Woude, George F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Biopraxis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; MITOGEN ACTIVATED PROTEIN KINASE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BACILLUS ANTHRACIS; ENZYME DEGRADATION; ENZYME INACTIVATION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TOXIN ANALYSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BINDING SITES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE, TRANSFORMED; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; METALLOENDOPEPTIDASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELIN BASIC PROTEINS; OOCYTES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; XENOPUS LAEVIS;

ANIMALIA; ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 18244414803     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5364.734     Document Type: Article

References (34)

1. S. H. Leppla, in Handbook of Natural Toxins, J. Moss, B. Iglewski, M. Vaughan, A. T. Tu, Eds. (Dekker, New York, 1995), vol. 8, pp. 543-572.
2. V. M. Gordon, S. H. Leppla, E. L. Hewlett, Infect. Immun. 56, 1066 (1988); J. C. Milne, D. Furlong, P. C. Hanna, J. S. Wall, R. J. Collier, J. Biol. Chem. 269, 20607 (1994).
3. V. M. Gordon, S. H. Leppla, E. L. Hewlett, Infect. Immun. 56, 1066 (1988); J. C. Milne, D. Furlong, P. C. Hanna, J. S. Wall, R. J. Collier, J. Biol. Chem. 269, 20607 (1994).
4. S. H. Leppla, Proc. Natl. Acad. Sci. U.S.A. 79, 3162 (1982).
5. C. Pezard, P. Berche, M. Mock, Infect. Immun. 59, 3472 (1991).
6. J. W. Ezzell, B. E. Ivins, S. H. Leppla, ibid. 45, 761 (1984).
7. A. M. Friedlander, J. Biol. Chem. 261, 7123 (1986).
8. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
9. K. R. Klimpel, N. Arora, S. H. Leppla, Mol. Microbiol. 13, 1093 (1994).
10. S. K. Kochi, G. Schiavo, M. Mock, C. Montecucco, FEMS Microbiol. Lett. 124, 343 (1994); A. Menard, E. Papini, M. Mock, C. Montecucco, Biochem. J. 320, 687 (1996).
11. S. K. Kochi, G. Schiavo, M. Mock, C. Montecucco, FEMS Microbiol. Lett. 124, 343 (1994); A. Menard, E. Papini, M. Mock, C. Montecucco, Biochem. J. 320, 687 (1996).
12. J. N. Weinstein et al., Science 275, 343 (1997); H.-M. Koo et al., Cancer Res. 56, 5211 (1996).
13. J. N. Weinstein et al., Science 275, 343 (1997); H.-M. Koo et al., Cancer Res. 56, 5211 (1996).
14. D. T. Dudley, L. Pang, S. J. Decker, A. J. Bridges, A. R. Saltiel, Proc. Natl. Acad. Sci. U.S.A. 92, 7686 (1995).
15. For reviews, see T. Moriguchi, Y. Gotoh, E. Nishida, Adv. Pharmacol. 36, 121 (1996); M. S. Murakami and G. F. Vande Woude, Methods Enzymol. 283, 584 (1997); W. T. Matten and G. F. Vande Woude, Sem. Dev. Biol. 5, 173 (1994).
16. For reviews, see T. Moriguchi, Y. Gotoh, E. Nishida, Adv. Pharmacol. 36, 121 (1996); M. S. Murakami and G. F. Vande Woude, Methods Enzymol. 283, 584 (1997); W. T. Matten and G. F. Vande Woude, Sem. Dev. Biol. 5, 173 (1994).
17. For reviews, see T. Moriguchi, Y. Gotoh, E. Nishida, Adv. Pharmacol. 36, 121 (1996); M. S. Murakami and G. F. Vande Woude, Methods Enzymol. 283, 584 (1997); W. T. Matten and G. F. Vande Woude, Sem. Dev. Biol. 5, 173 (1994).
18. N. S. Duesbery and G. F. Vande Woude, unpublished data.
19. M. Glotzer, A. W. Murray, M. W. Kirschner, Nature 349, 132 (1991).
20. M. A. White et al., Cell 80, 533 (1995).
21. Y. Singh, K. R. Klimpel, N. Arora, M. Sharma, S. H. Leppla, J. Biol. Chem. 269, 29039 (1994).
22. S. Mansour, J. M. Candia, K. K. Gloor, N. G. Ahn, Cell Growth Differ. 7, 243 (1996); S. J. Mansour et al., Science 265, 966 (1994).
23. S. Mansour, J. M. Candia, K. K. Gloor, N. G. Ahn, Cell Growth Differ. 7, 243 (1996); S. J. Mansour et al., Science 265, 966 (1994).
24. Wild-type MAPKK1 (0.5 μg) was incubated with LF (0.2 μg) as described in Fig. 2A for 30 min at 30°C. Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto polyvinylidene difluoride membrane in CAPS transfer buffer {3-[cyclohexylamino]-1 propanesulfonic acid (10 mM, pH 11) and 10% methanol) at 300 mA constant current for 30 min. After transfer, membranes were quickly stained with Ponceau S solution (0.1% Ponceau S and 5% acetic acid) and rinsed with distilled deionized water. The appropriate band was cut from the membrane and subjected to automated Edman degradation in an Applied Biosystems 477A gas-phase sequencer, and phenylthiohydantoin derivatives were identified online with a 120 phenylthiohydantoin analyzer.
25. S. J. Mansour, J. M. Candia, J. E. Matsuura, M. C. Manning, N. G. Ahn, Biochemistry 35, 15529 (1996).
26. M. Fukuda, Y. Gotoh, E. Nishida, EMBO J. 16, 1901 (1997).
27. S. E. Hammond and P. C. Hanna, abstract presented at the 97th General Meeting of the American Society of Microbiology, Miami Beach, FL (1997).
28. N. S. Duesbery et al., Proc. Natl. Acad. Sci. USA 94, 9165 (1997).
29. S. H. Leppla, Methods Enzymol. 165, 103 (1988).
30. E. K. Shibuya, T. G. Boulton, M. H. Cobb, J. V. Ruderman, EMBO J. 11, 3963 (1992).
31. N. Yew, M. L. Mellini, G. F. Vande Woude Nature 355, 649 (1992).
32. 2, 0.35 μg of MAPK [ERK2; D. J. Robbins et al., J. Biol. Chem. 268, 5097 (1993)], and 10 μg of MBP (Upstate Biotechnology)} was added, and samples were incubated for a further 15 min at 30°C. Proteins were separated by SDS-PAGE on 14% gels and processed for autoradiography.
33. 2+-charged HiTrap Chelating column (Pharmacia), washed with EB containing 10 mM imidazole, and eluted with EB containing 200 mM imidazole. Fractions containing recombinant protein were then pooled and desalted and concentrated in buffer containing 50 mM tris (pH 8.0), 0.1 M NaCl, 10% glycerol, 0.01% Triton X-100, and 1 mM DTT by centrifugation with a Centriprep-30 centrifugal concentrator (Amicon, Beverely, MA, XX).
34. This paper is dedicated to the memory of Ken Paull, whose untimely death is a significant toss to NCl and the cancer research community. The authors thank A. Cline and R. Frederickson for preparing the manuscript, L. Miller for technical assistance, H.-M. Koo for helpful discussions, M. Jeffers and S. Koochekpour for critical comments on the manuscript, and A. Murray for providing A90 cyclin. This research was sponsored in part by NCl, Department of Health and Human Services, under contract with Advanced BioScience Laboratories. By acceptance of this article, the publisher or recipient acknowledges the right of the U.S. government and its contractors and agents to retain a nonexclusive royalty-free license in and to any copyright covering the article.